Lederle beta blocker license
Executive Summary
Lederle will market bisoprolol, a "third generation cardioselective" beta blocker developed by E. Merck (Germany), in the U.S. and Canada. The once-a-day product, licensed through E. Merck's U.S. affiliate E.M. Industries, is approved in West Germany where a launch is planned for this spring, with marketing in other European countries to follow within two years, Lederle said. Lederle will handle NDA filing based on U.S. clinical data from ongoing studies sponsored by E.M. Industries.
You may also be interested in...
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Device Week, 21 January 2021 – EY M&A Firepower; JPM, NANS Events Highlights; CorWave Profile
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Q&A: Renalytix AI Prez Explains How MCIT Rule Will Aid Kidney Product Coverage By CMS
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: